By Yafo Life Sciences
December 22nd, 2021 (Shanghai) — We are glad to announce that Joo-Cheol Park, the CEO of HysensBio Co., Ltd., has been invited to showcase at ACCESS CHINA Biotech Forum at 15:00, Jan 4th, 2022 (China Time, GMT+8:00). ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
If you are interested in listening to the live event, please register at https://biotochina.org/register/
About HysensBio Co., Ltd.
HysensBio is a clinical stage company developing novel peptide drug through regenerative therapy. Its leading pipeline KH001 treats tooth sensitivity, dental caries, and periodontitis by regenerating physiologic dentin. Currently, phase 1/2a clinical studies for dentin hypersensitivity indication is ongoing in South Korea. HysensBio is in search of partners for licensing out of KH001 to regional/worldwide territory except for South Korea.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: